Full Year 2021 Product Sales
The following table provides the top 20 Innovative Medicines Division product net sales in 2021 as well as the change compared to 2020:
| Brands |
Net Sales (USD m) |
% change (USD) |
Business Franchise |
|---|---|---|---|
| Cosentyx | 4,718 | 18% | Immunology, Hepatology and Dermatology |
| Entresto | 3,548 | 42% | Cardiovascular, Renal and Metabolism |
| Gilenya | 2,787 | -7% | Neuroscience |
| Lucentis | 2,160 | 12% | Ophthalmology |
| Tasigna | 2,060 | 5% | Hematology |
| Promacta/Revolade | 2,016 | 16% | Hematology |
| Tafinlar + Mekinist | 1,693 | 10% | Solid Tumor |
| Jakavi | 1,595 | 19% | Hematology |
| Xolair1 | 1,428 | 14% | Respiratory and Allergy |
| Sandostatin | 1,413 | -2% | Solid Tumor |
| Zolgensma | 1,351 | 47% | Neuroscience |
| Galvus Group | 1,092 | -9% | Established Medicines |
| Ilaris | 1,059 | 21% | Immunology, Hepatology and Dermatology |
| Gleevec/Glivec | 1,024 | -14% | Hematology |
| Afinitor/Votubia | 938 | -13% | Solid Tumor |
| Kisqali | 937 | 36% | Solid Tumor |
| Exforge Group | 901 | -8% | Established Medicines |
| Diovan Group | 773 | -23% | Established Medicines |
| Kymriah | 587 | 24% | Hematology |
| Ultibro Group | 584 | -6% | Respiratory and Allergy |